Alx Oncology

Alx Oncology company information, Employees & Contact Information

Explore related pages

Related company profiles:

ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications.

Company Details

Employees
73
Founded
-
Address
323 Allerton Ave, South San Francisco,california 94080,united States
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
South San Francisco, California
Looking for a particular Alx Oncology employee's phone or email?

Alx Oncology Questions

News

ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025 - GlobeNewswire

ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025 GlobeNewswire

ALX Oncology to Participate in Upcoming Investor Conferences in September - Yahoo Finance

ALX Oncology to Participate in Upcoming Investor Conferences in September Yahoo Finance

ALX Oncology Presents Phase 2 ASPEN-06: CD47 Biomarker in HER2+ Gastric Cancer | ALXO Stock News - Stock Titan

ALX Oncology Presents Phase 2 ASPEN-06: CD47 Biomarker in HER2+ Gastric Cancer | ALXO Stock News Stock Titan

ALX Oncology Holdings Inc. to Report Second Quarter 2025 Financial Results and Business Update on August 12, 2025 | ALXO Stock News - Quiver Quantitative

ALX Oncology Holdings Inc. to Report Second Quarter 2025 Financial Results and Business Update on August 12, 2025 | ALXO Stock News Quiver Quantitative

ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 - GlobeNewswire

ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 GlobeNewswire

ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer - Yahoo Finance

ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer Yahoo Finance

Clinical-Stage Biotech ALX Oncology Announces Dual Conference Presentations in September 2025 - Stock Titan

Clinical-Stage Biotech ALX Oncology Announces Dual Conference Presentations in September 2025 Stock Titan

ALX Oncology Appoints Dr. Barbara Klencke as Interim Chief Medical Officer Following Departure of Dr. Alan Sandler - Quiver Quantitative

ALX Oncology Appoints Dr. Barbara Klencke as Interim Chief Medical Officer Following Departure of Dr. Alan Sandler Quiver Quantitative

ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference - Yahoo Finance

ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference Yahoo Finance

ALX Oncology Sets Date for Q2 2025 Earnings: Key Business Updates Expected from Cancer Drug Pipeline - Stock Titan

ALX Oncology Sets Date for Q2 2025 Earnings: Key Business Updates Expected from Cancer Drug Pipeline Stock Titan

ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Yahoo Finance

ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update Yahoo Finance

First-in-Class EGFR Cancer Drug: ALX Oncology Launches Groundbreaking Phase 1 Trial for Solid Tumors - Stock Titan

First-in-Class EGFR Cancer Drug: ALX Oncology Launches Groundbreaking Phase 1 Trial for Solid Tumors Stock Titan

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 - Yahoo Finance

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 Yahoo Finance

ALX Oncology Doses First Patient in Phase 1 Dose Escalation - GlobeNewswire

ALX Oncology Doses First Patient in Phase 1 Dose Escalation GlobeNewswire

ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event - Yahoo Finance

ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event Yahoo Finance

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials - GlobeNewswire

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials GlobeNewswire

ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - Yahoo Finance

ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 Yahoo Finance

ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate - Yahoo Finance

ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate Yahoo Finance

ALX Oncology Announces Preclinical Data and Phase 1 - GlobeNewswire

ALX Oncology Announces Preclinical Data and Phase 1 GlobeNewswire

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire

ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update GlobeNewswire

ALX Oncology Presents Promising Preclinical Data for ALX2004, a Novel ADC Targeting EGFR-Expressing Solid Tumors at 2025 AACR-NCI-EORTC Conference - Quiver Quantitative

ALX Oncology Presents Promising Preclinical Data for ALX2004, a Novel ADC Targeting EGFR-Expressing Solid Tumors at 2025 AACR-NCI-EORTC Conference Quiver Quantitative

ALX Oncology's Cancer Treatment Breakthrough: New Biomarker Predicts 2.5x Better Response in Gastric Cancer - Stock Titan

ALX Oncology's Cancer Treatment Breakthrough: New Biomarker Predicts 2.5x Better Response in Gastric Cancer Stock Titan

30-Year Oncology Veteran Dr. Barbara Klencke Takes Helm as ALX Oncology's New Interim CMO - Stock Titan

30-Year Oncology Veteran Dr. Barbara Klencke Takes Helm as ALX Oncology's New Interim CMO Stock Titan

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma - GlobeNewswire

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma GlobeNewswire

ALX Oncology Announces Further Additions to Leadership Team - GlobeNewswire

ALX Oncology Announces Further Additions to Leadership Team GlobeNewswire

ALX Oncology Presents Positive Updated Data from ASPEN-06 - GlobeNewswire

ALX Oncology Presents Positive Updated Data from ASPEN-06 GlobeNewswire

ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 - GlobeNewswire

ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 GlobeNewswire

ALX Oncology Presents First Evorpacept Combination Data - GlobeNewswire

ALX Oncology Presents First Evorpacept Combination Data GlobeNewswire

Knowledge Management in QMS: Improving Business Growth - BioProcess International

Knowledge Management in QMS: Improving Business Growth BioProcess International

ALX Oncology Announces September Investor Conference Participation - MarketScreener

ALX Oncology Announces September Investor Conference Participation MarketScreener

ALX Oncology Announces Initial Data from ASPEN-02, the - GlobeNewswire

ALX Oncology Announces Initial Data from ASPEN-02, the GlobeNewswire

ALX Oncology Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio - GlobeNewswire

ALX Oncology Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio GlobeNewswire

ALX Oncology Announces Updates on Planned ALX148 Phase 2 Head and Neck Cancer Studies - GlobeNewswire

ALX Oncology Announces Updates on Planned ALX148 Phase 2 Head and Neck Cancer Studies GlobeNewswire

Top Alx Oncology Employees

  • Harish Shantharam, CFA

    Harish Shantharam, CFA

    n/a

    San Mateo, California, United States, United States
    4
    gilead.com, gmail.com, amgen.com, cymabay.com
  • Rekha Hemrajani

    Rekha Hemrajani

    n/a

    San Francisco Bay Area, United States
    11
    gmail.com, exelixis.com, flxbio.com, 3vbio.com, onyx.com, lehman.com, pacbell.net, jiyacorp.com, arcusbio.com, exelixis.com, flxbio.com

    11 +165055XXXXX

  • Julie Bacon

    Julie Bacon

    n/a

    Edmonds, Washington, United States, United States
  • Nathan Pofahl

    Nathan Pofahl

    Learning Leader

    Vacaville, California, United States, United States
    5
    gene.com, roche.com, hotmail.com, hotmail.com, ultragenyx.com

    3 +160869XXXXX

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant